EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Search
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
Ukraine Help: In a nine-seater to Poland
Boehringer Ingelheim employee Eugen Pushchyk rescues refugees from Ukraine
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Rafał Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
3 tips for anyone interested in a STEM career
What does it take to pursue a career in science? We asked Dr. Joanne Maki, a Boehringer Ingelheim veterinarian and scientist based in Athens, Ga.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Your dog’s life stages: dog health from puppy to adult and senior
The needs of dogs change as they age. Find out how to take care of their health at all stages of life: from puppy to adult and senior.
How do our donations for Ukraine help?
The war in Ukraine continues to cause suffering and hardship. The Polish and the German Red Cross – also supported by donations from us – help to the best of their ability.
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
Siva Thotapalli
My career challenge at Boehringer Ingelheim by Siva Thotapalli. Read it now!
Are you missing the bigger picture on mental health?
Revolutionizing our approach to serious mental health conditions is crucial for tailored care, placing those with lived experience at the center.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
On the road with sanitation workers in India
Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
India: Many positive developments for the population
A conversation with interim country manager Sandip Agrawal about a young and growing country